[关键词]
[摘要]
目的 探讨金芪降糖片联合西格列汀治疗2型糖尿病的临床疗效。方法 选取北京电力医院于2021年7月—2023年6月收治糖尿病患者120例,随机分为对照组和治疗组,每组各60例。对照组口服磷酸西格列汀片,100 mg/次,1次/d。治疗组在对照组基础上口服金芪降糖片,1.68 g/次,3次/d。两组患者均治疗3个月。观察两组患者临床疗效,比较治疗前后两组患者3个月内三点主要不良心血管事件(3p-MACE)发生率,糖化血红蛋白(HbA1c)、空腹血糖(FBG)及餐后2 h血糖(2 h PBG)、内皮素(ET-1)、一氧化氮(NO)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)和白细胞介素-6(IL-6)水平。结果 治疗后,治疗组患者总有效率为93.33%,对照组患者总有效率为78.33%,两组比较差异有统计学意义(P<0.05)。治疗后,两组FBG、2 h PBG、HbA1c、TNF-α、CRP、IL-6和ET1水平较治疗前明显降低,而NO水平较治疗前明显升高(P<0.05),且治疗后治疗组血糖水平、微炎症和血管内皮功能均明显好于对照组(P<0.05)。结论 金芪降糖片联合西格列汀能有效降低2型糖尿病患者血糖,改善微炎症及保护血管内皮。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Jinqi Jiangtang Tablets combined with sitagliptin in treatment of type 2 diabetes. Methods Patients (120 cases) with type 2 diabetes in Beijing Electric Power Hospital from July 2021 to June 2023 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Jinqi Jiangtang Tablets on the basis of the control group, 1.68 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluations were evaluated, and the 3p-MACE of 3 months, the levels of FBG, 2 h PBG, HbA1c, NF-α, CRP, IL-6, NO and ET1 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.33%, and which in the control group was 78.33%, there was a statistically significant difference between the two groups (P < 0.05). After treatment, the levels of FBG, 2 h PBG, HbA1c, TNF-α, CRP, IL-6 and ET1 in two groups were significantly lower than before treatment, while the level of NO was significantly higher than before treatment (P < 0.05). After treatment, the blood sugar level, micro-inflammation and vascular endothelial function in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Jinqi Jiangtang Tablets combined with sitagliptin can effectively reduce blood glucose, improve micro-inflammation and protect vascular endothelium in patients with type 2 diabetes.
[中图分类号]
R977
[基金项目]